APA (7th ed.) Citation

S, C., S, H., A, A., B, P., A, T., & D, B. (2026). Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: A case report. Frontiers in oncology, 16, 1795399. https://doi.org/10.3389/fonc.2026.1795399

Chicago Style (17th ed.) Citation

S, Chandra, Hansraj S, Adhikari A, Ponvilawan B, Tolentino A, and Bansal D. "Successful Rechallenge of BRAF/MEK Inhibitor with Ruxolitinib in BRAF/MEK Inhibitor-induced Hemophagocytic Lymphohistiocytosis like Hyperinflammatory Syndrome in BRAF V600E-mutated Lung Adenocarcinoma: A Case Report." Frontiers in Oncology 16 (2026): 1795399. https://doi.org/10.3389/fonc.2026.1795399.

MLA (9th ed.) Citation

S, Chandra, et al. "Successful Rechallenge of BRAF/MEK Inhibitor with Ruxolitinib in BRAF/MEK Inhibitor-induced Hemophagocytic Lymphohistiocytosis like Hyperinflammatory Syndrome in BRAF V600E-mutated Lung Adenocarcinoma: A Case Report." Frontiers in Oncology, vol. 16, 2026, p. 1795399, https://doi.org/10.3389/fonc.2026.1795399.